VistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

VistaGen Therapeutics (NASDAQ:VTGN) announced its quarterly earnings results on Friday. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06, FiscalAI reports. VistaGen Therapeutics had a negative net margin of 5,487.01% and a negative return on equity of 133.02%. The firm had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $0.50 million.

VistaGen Therapeutics Price Performance

VTGN opened at $0.27 on Friday. The firm has a market capitalization of $11.88 million, a PE ratio of -0.16 and a beta of 0.41. The business’s 50-day moving average is $0.37 and its two-hundred day moving average is $0.51. VistaGen Therapeutics has a 1 year low of $0.20 and a 1 year high of $5.14.

Institutional Trading of VistaGen Therapeutics

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new position in shares of VistaGen Therapeutics during the 4th quarter worth approximately $25,000. Cubist Systematic Strategies LLC acquired a new stake in VistaGen Therapeutics in the first quarter valued at approximately $25,000. Schonfeld Strategic Advisors LLC purchased a new position in VistaGen Therapeutics in the third quarter worth $39,000. Tudor Investment Corp ET AL purchased a new position in VistaGen Therapeutics in the fourth quarter worth $50,000. Finally, Bank of America Corp DE increased its position in shares of VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares in the last quarter. 78.39% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, VistaGen Therapeutics currently has an average rating of “Reduce” and a consensus target price of $0.95.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.